Foamix Ltd.   Report issue

For profit Phase 2 Phase 3 Phase 4
Founded: Rehovot Israel (2003)
Status: No NME R&D (2003)

Organization Overview

First Clinical Trial
2010
NCT01134991
First Marketed Drug
2019
minocycline (minocin)
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

FOAMIX | Foamix Ltd.

Active Ingredients

Marketed Drugs (1)

Key: Foamix Ltd. (0) Acquired (1)

minocycline (minocin) (2019)

Drugs in Phase 4 Trials (2)

Key: Foamix Ltd. (0) Acquired (2)

isotretinoin (accutane) (1 trial)

minocycline (minocin) (17 trials)

Drugs in Phase 3 Trials (1)

Key: Foamix Ltd. (0) Acquired (1)

serlopitant (12 trials)

Drugs in Phase 2 Trials (5)

Key: Foamix Ltd. (3) Acquired (2)

adapalene (differin) (1 trial)

ark-e021 (1 trial)

doxycycline (vibramycin) (1 trial)

fingolimod (gilenya) (1 trial)

tofacitinib (xeljanz) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acne Vulgaris (Phase 3)

Dermatitis, Phototoxic (Phase 1)

Facies (Phase 3)

Impetigo (Phase 2)

Rosacea (Phase 3)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 32
  • # of Trial APIs: 8